Dicerna.com Website Review

boehringer ingelheim exercises option on second hepatic disease target from research collaboration with dicerna dicerna is developing a pipeline of innovative rnai therapies using our galxctm rnai platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. dr. ralf rosskamp, dicerna’s chief medical officer, participated in podcast with rarecast and provided an overview of the challenges facing drug development in rare diseases, as well as an update on dicerna’s development program in primary hyperoxaluria. galxctm is a proprietary rnai technology platform that advances the development of next-generation rnai-based therapies that act by silencing disease-driving genes in the liver. galxc molecules are designed for infrequent subcutaneous administration. genes known to cause or drive disease. in the rnai process, small, carefully selected molecules of rna inhibit the expression of these harmful genes by causing the targeted destruction of their messenger rnas (mrnas). rnai has the potential to generate a revolution in. nobel prize in physiology or medicine is awarded to fire and mello for their discovery of rnai.. dicerna is issued a u.s. patent to broadly cover dsirna technology.. dicerna is issued a u.s. patent to broadly cover dicerna’s extended dicer substrate™ (dsirna-ex) thera*eutic rnas.. dicerna initiates a phase 1 study of dcr-myc in patients with solid tumors and hematologic malignancies.. dicerna presents preclinical data indicating the rapid and durable effect of dcr-ph1 in a mouse model of primary hyperoxaluria type 1. (ph1), at the 10th annual meeting of the oligonucleotide thera*eutics society in san diego, calif.. dicerna announces successful delivery of dsirna-ex conjugate molecules in an*mals using subcutaneous injection.. dicerna introduces galxc, a proprietary next-generation rnai technology platform, to rapidly identify new thera*eutic agents that.